Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Sub-Licenses Genomic Engineering IP to GlaxoSmithKline

NEW YORK (GenomeWeb News) — Cellectis has sub-licensed to GlaxoSmithKline patents for a process used to replace, remove, or insert genes in a genome by homologous recombination, Cellectis said Friday.
 
The company, which licensed the technology from the Pasteur Institute, said GlaxoSmithKline will use it in its drug research for in vitro and in vivo “modifications and manipulations of genetic material.”
 
Cellectis said the homologous recombination technology is commonly used by life scientists to generate mouse models with altered genomes in disease and gene-function studies.
 
Financial terms of the agreement were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.